3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
4
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Stomach Neoplasms
2
Interventions
Oxaliplatin
21
pembrolizumab
17
Capecitabine
15
Nivolumab
13
Paclitaxel
12
Fluorouracil
12
Leucovorin
11
Docetaxel
10
atezolizumab
7
Trastuzumab
7
tislelizumab
5
Ramucirumab
5
durvalumab
4
Standard of Care
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
Cisplatin
4
Carboplatin
4
zolbetuximab
3
zimberelimab
3
apatinib
3
Specimen Handling
3
S 1 (combination)
3
Gemcitabine
3
Bevacizumab
3
trifluridine tipiracil drug combination
2
tremelimumab
2
trastuzumab deruxtecan
2
relatlimab
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Stomach Neoplasms
×
bemarituzumab
×
Clear all
NCT05111626
2025-12-15
FORTITUDE-102
Amgen
Phase 3
Active not recruiting
515 enrolled
NCT05322577
2025-12-05
FORTITUDE-103
Amgen
Phase 1/2
Active not recruiting
72 enrolled